An update on immunotherapy in uro-oncology

References

• Junker K, Eckstein M, Fiorentino M, et al. PD1/PD-L1 axis in uro-oncology. Curr Drug Targets. 2020;21(13):1293–1300.
   PubMed Web of Science ®Google Scholar
• Seliger B. Basis of PD1/PD-L1 therapies. J Clin Med. 2019;8(12):2168.
   PubMed Web of Science ®Google Scholar
• Giunchi F, Gevaert T, Scarpelli M, et al. Status of programmed death ligand 1 (PD-L1) by immunohistochemistry and scoring algorithms. Curr Drug Targets. 2020;21(13):1286–1292.
   PubMed Web of Science ®Google Scholar
• Gevaert T, Cimadamore A, Eckstein M, et al. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Future Oncol. 2019;15(19):2199–2202.
   PubMed Web of Science ®Google Scholar
• Suzman DL, Agrawal S, Ning YM, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019;24(4):563–569.
   PubMed Web of Science ®Google Scholar
• Eckstein M, Cimadamore A, Hartmann A, et al. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2019;7(22):690.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–322.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197-218.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Cheng L, et al. PD-L1 inhibitors for the treatment of prostate cancer. Curr Drug Targets. 2020;21(15):1558–1565.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Cimadamore A, et al. Is there a role for immunotherapy in prostate cancer?. Cells. 2020;9(9):2051.
   PubMed Web of Science ®Google Scholar
• Fay EK, Graff JN. Immunotherapy in prostate cancer. Cancers (Basel). 2020;12(7):1752.
   PubMed Web of Science ®Google Scholar
• Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and treg skewing. Clin Cancer Res. 2008;14(11):3254–3261.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Di Nunno V, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212528.
   PubMedGoogle Scholar
• Cimadamore A, Massari F, Santoni M, et al. PD1 and PD-L1 Inhibitors for the treatment of kidney cancer: the role of PD-L1 assay. Curr Drug Targets. 2020;21(16):1664–1671.
   PubMed Web of Science ®Google Scholar
• Bakouny Z, Braun DA, Shukla SA, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12(1):808.
   PubMed Web of Science ®Google Scholar
• Graham J, Wells C, Dudani S, et al. Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(suppl 6):316.
   Web of Science ®Google Scholar
• Cheng X, Dai H, Wan N, et al. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege. Transplantation. 2009;87(12):1778–1786.
   PubMed Web of Science ®Google Scholar
• Fankhauser C, Curioni-Fontecedro A, Allmann V, et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer. 2015;113(3):411–413.
   PubMed Web of Science ®Google Scholar
• Cierna Z, Mego M, Miskovska V, et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol. 2016;27(2):300–305.
   PubMed Web of Science ®Google Scholar
• Adra N, Einhorn LH, Althouse SK, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a hoosier cancer research network study GU14-206. Ann Oncol. 2018;29(1):209–214.
   PubMed Web of Science ®Google Scholar
• Necchi A, Bratslavsky G, Chung J, et al. Genomic features for therapeutic insights of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors and comparison with gonadal counterpart. Oncologist. 2019;24(4):e142–e5.
   PubMed Web of Science ®Google Scholar
• Mego M, Svetlovska D, Chovanec M, et al. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. Invest New Drugs. 2019;37(4):748–754.
   PubMed Web of Science ®Google Scholar
• Udager AM, Liu TY, Skala SL, et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016;27(9):1706–1712.
   PubMed Web of Science ®Google Scholar
• Santoni M, Heng DYC, Aurilio G, et al. Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in renal cell carcinoma. Curr Drug Targets. 2020;21(4):416–423.
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11(10):702–711.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Aurilio G, et al. Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy. 2020;12(17):1257–1268.
   PubMed Web of Science ®Google Scholar
• Pandha H, Pawelec G. Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015. Cancer Immunol Immunother. 2015;64(9):1071–1074.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. ESMO guidelines committee. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706–720.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. PMID: 33657295 N Engl J Med. 2021;3849:829–841.
   PubMed Web of Science ®Google Scholar
• Massari F, Mollica V, Rizzo A, et al. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(10):1329–1338.
   PubMed Web of Science ®Google Scholar
• Al Harthy M, Redman J, Madan RA. Novel immunotherapy combinations for genitourinary cancers. Exp Opin Biol Ther. 2020;20(3):253–262.
   PubMed Web of Science ®Google Scholar